More generally, the RAS signalling pathway has been found to be fundamental in the development of myeloid malignancies, with somatic activating mutations in NRAS and KRAS genes estimated to be present in 20 to 40% of diagnosed cases of AML, CMML and JMML [81]. The gene discussed is KRAS; the disease is myeloid neoplasm.